In subjects with mild, moderate or severe hepatic impairment (Child-Pugh A-C) there were no clinically significant changes (maximum ~30%) in exposure to vildagliptin.
En pacientes con insuficiencia hepática leve, moderada o grave (Child-Pugh A-C) no se observaron cambios clínicamente significativos (máximo ~30%) en la exposición a vildagliptina.